Platelets

Papers
(The TQCC of Platelets is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
High rate of extreme thrombocytosis indicates bone marrow hyperactivity and splenic dysfunction among congenital diaphragmatic hernia patients59
Prostacyclin analogues decrease platelet aggregation but have no effect on thrombin generation, fibrin clot structure, and fibrinolysis in pulmonary arterial hypertension: PAPAYA coagulation41
Contributing role of mitochondrial energy metabolism on platelet adhesion, activation and thrombus formation under blood flow conditions34
Predictive performance of different bleeding risk scores in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention30
Platelet-derived microparticles stimulated by anti-β 2 GPI/β 2 GPI complexes induce pyroptosis of endothelial cells in antiphospho28
Trends among platelet function, arterial calcium, and vascular function measures26
Development of an automated chemiluminescence enzyme immunoassay for the measurement of soluble C-type lectin-like receptor 2 (sCLEC-2) and molecular forms of sCLEC-2 measured in patient plasma25
Enhanced platelet sensitization is accompanied by increased expression of the transporter MRP4 and elevated plasma S1P levels in mild COVID-19 convalescents24
Apoptosis is one cause of thrombocytopenia in patients with high-altitude polycythemia23
How can we use proteomics to learn more about platelets?22
The role of miRNAs in regulation of platelet activity and related diseases - a bioinformatic analysis20
Clinical features and treatment effect of HIV-associated immune thrombocytopenia—single center Ten-Years data summary18
Sex-specific relationship between blood selenium levels and platelet count in a large cohort representative of the United States population18
Platelets and open access – a new era dawns16
Crushed/chewed administration of potent P2Y12 inhibitors in ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Systematic review and meta-anal16
Dual antiplatelet therapy is associated with high α-tubulin acetylation in circulating platelets from coronary artery disease patients15
Increased circulating platelet-derived extracellular vesicles in severe COVID-19 disease14
The natural anticoagulant protein S; hemostatic functions and deficiency14
Chronic immune thrombocytopenia in a child with X-linked agammaglobulinemia-an uncommon phenotype14
Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial13
Pro106Leu MPL mutation is associated with thrombocytosis and a low risk of thrombosis, splenomegaly and marrow fibrosis13
Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia13
Extracellular thiol isomerase ERp5 regulates integrin αIIbβ3 activation by inhibition of fibrinogen binding13
Tirofiban potentiates agonist-induced platelet activation and degranulation, despite effectively inhibiting aggregation12
Potential mechanisms involved on how systemic IgG antibodies specific to vascular endothelial growth factor (VEGF) and induced by active immunotherapy decrease platelet derived free-VEGF12
Significance of mild thrombocytopenia in maintenance hemodialysis patients; a retrospective cohort study12
Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study12
Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure11
European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia11
Platelet response to aspirin in UK and Irish pregnancy cohorts: a genome-wide approach11
Apolipoprotein A-I, elevated in trauma patients, inhibits platelet activation and decreases clot strength11
Variation in activation marker expression within the platelet population – a new parameter for evaluation of platelet flow cytometry data11
Recent advances in microfluidic technology of arterial thrombosis investigations10
Inflammation modifies the platelet reactivity among thrombocytopenia patients undergoing percutaneous coronary intervention10
Potential and limitations of PKA/ PKG inhibitors for platelet studies10
Phosphorylation of (Ser 291) in the linker insert of Syk negatively regulates ITAM signaling in platelets10
Developmental differences of in vitro cultured murine bone marrow- and fetal liver-derived megakaryocytes10
Impact of thrombocytopenia-associated c.-118C>T and c.-140C>G ANKRD26 5’UTR variants in three-generational pedigree10
Evolution of platelet activation parameters during septic shock in intensive care unit10
Circulating microRNAs as biomarkers and mediators of platelet activation10
Higher body mass index raises immature platelet count: potential contribution to obesity-related thrombosis9
Role of platelet count in a murine stasis model of deep vein thrombosis9
Evaluation of human platelet granules by structured illumination laser fluorescence microscopy9
Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology9
In memory of Dr. Susan S. Smyth, MD/Ph.D.9
Deep learning, 3D ultrastructural analysis reveals quantitative differences in platelet and organelle packing in COVID-19/SARSCoV2 patient-derived platelets9
EloA promotes HEL polyploidization upon PMA stimulation through enhanced ERK1/2 activity9
Neurosurgical bleeding in platelet storage pool disorder: a case report9
Identification of UDP-Glucuronosyltransferase mRNA in human platelets: differential levels in smokers and non-smokers9
A splice mutation in RASGRP2 gene in the patient with recurrent epistaxis and nasal vascular malformation9
Association of thromboxane generation with the bleeding events in aspirin users9
Early recognition of sepsis-induced coagulopathy using the C2PAC index: a ratio of soluble type C lectin-like receptor 2 (sCLEC-2) level and platelet count9
Cardiometabolic risk factor burden associates with an immature platelet profile8
The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention8
Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study8
Congenital thrombocytopenia associated with a heterozygous variant in the MEIS1 gene encoding a transcription factor essential for megakaryopoiesis8
What can we learn from senescent platelets, their transcriptomes and proteomes?8
miR-28-5p targeted Rap1b attenuates splenic inflammation infiltration in immune thrombocytopenia8
Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective8
Age and outcomes following personalized antiplatelet therapy in chronic coronary syndrome patients: a post hoc analysis of the randomized PATH-PCI trial8
Application of the Cellular Thermal Shift Assay (CETSA) to validate drug target engagement in platelets8
Factors influencing platelet isolation: a prospective multicenter study from Western China8
Platelet-derived respiratory-competent mitochondria transfer to mesenchymal stem cells to promote wound healing via metabolic reprogramming8
Multiple myeloma and its treatment contribute to increased platelet reactivity8
Thrombocytopathy vs Platelet hyper-reactivity in COVID-19: diverse pathologies, disease outcomes and therapeutic implications7
Evaluating stored platelet shape change using imaging flow cytometry7
Platelet index on admission as a predictor of bacteremia in acute cholangitis: a 7-year retrospective observational study7
Deficiency of BLOS1 moderately impairs the biogenesis of platelet dense granules7
In vitro evaluation of platelet extracellular vesicles (PEVs) for corneal endothelial regeneration7
Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia7
Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors7
Q94 is not a selective modulator of proteinase-activated receptor 1 (PAR1) in platelets7
Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies7
New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans7
0.54734396934509